4.4 Article

Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress

Journal

MEDICAL ONCOLOGY
Volume 39, Issue 5, Pages -

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12032-022-01657-4

Keywords

Glioblastoma; Recurrence; ATM; ATR; Radioresistant

Categories

Funding

  1. Department of Biotechnology [BT/PR4020/MED/30/792/2012]

Ask authors/readers for more resources

The primary treatment modality for glioblastoma (GBM) after surgery is radiation therapy. However, due to the increased DNA damage repair capacity of resistant residual GBM cells, recurrence is inevitable and the recurrent tumors become resistant to conventional therapy. This study shows that recurrent GBM cells utilize an alternate DNA damage repair kinase to overcome radiation-induced DNA damage, indicating the underlying heterogeneity within and across GBM samples.
Primary treatment modality for glioblastoma (GBM) post-surgery is radiation therapy. Due to increased DNA damage repair capacity of resistant residual GBM cells, recurrence is inevitable in glioblastoma and unfortunately the recurrent tumours are resistant to the conventional therapy. Here we used our previously described in vitro radiation survival model generated from primary GBM patient samples and cell lines, which recapitulates the clinical scenario of therapy resistance and relapse. Using the parent and recurrent GBM cells from these models, we show that similar to parent GBM, the recurrent GBM cells also elicit a competent DNA damage response (DDR) post irradiation. However, the use of apical DNA damage repair sensory kinase (ATM and/or ATR) is different in the recurrent cells compared to parent cells. Consistently, we demonstrate that there is a differential clonogenic response of parent and recurrent GBM cells to the ATM and ATR kinase inhibitors with recurrent samples switching between these sensory kinases for survival emphasizing on the underlying heterogeneity within and across GBM samples. Taken together, here we report that recurrent tumours utilize an alternate DDR kinase to overcome radiation induced DNA damage. Since there is no effective treatment specifically for recurred GBM patients, these findings provide a rationale for developing newer treatment option to sensitize recurrent GBM samples by detecting in clinics the ability of cells to activate a DNA damage repair kinase different from their parent counterparts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available